{
      "Rank": 173,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "The volunteers of the experimental group will be given peripheral intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cells at 0,8,16,24,32 week.",
            "The control group will be given the same dose of saline containing human albumin."
      ],
      "ArmGroupInterventionName": [
            "Biological: human umbilical cord mesenchymal stem cells",
            "Other: saline"
      ],
      "ArmGroupLabel": [
            "experimental group",
            "control group"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04216849"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The study was a 48-week multicenter, randomized, double-blind, placebo-controlled trial that included 8 weeks of pre-screening and lifestyle education, 32 weeks of treatment, and 16 weeks of follow-up.To observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion in Chinese patients with type 2 diabetic nephropathy who received traditional hypoglycemic therapy."
      ],
      "BriefTitle": [
            "Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy"
      ],
      "CentralContactEMail": [
            "wcr601@163.com",
            "liu.zhongmin@tongji.edu.cn"
      ],
      "CentralContactName": [
            "Congrong Wang, MD",
            "Zhongming Liu, MD"
      ],
      "CentralContactPhone": [
            "+86-021-38804518",
            "+86-021-38804518"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "Chinese PLA General Hospital"
      ],
      "CompletionDate": [
            "July 1, 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Type 2 Diabetes With Renal Manifestations"
      ],
      "ConditionAncestorId": [
            "D000014570",
            "D000048909",
            "D000003920",
            "D000004700"
      ],
      "ConditionAncestorTerm": [
            "Urologic Diseases",
            "Diabetes Complications",
            "Diabetes Mellitus",
            "Endocrine System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC18",
            "BC19",
            "All",
            "BXS"
      ],
      "ConditionBrowseBranchName": [
            "Nutritional and Metabolic Diseases",
            "Gland and Hormone Related Diseases",
            "All Conditions",
            "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Nephropathy",
            "Diabetic Nephropathy"
      ],
      "ConditionBrowseLeafId": [
            "M6267",
            "M9850",
            "M6271",
            "M6275",
            "M16471",
            "M25157",
            "M7014"
      ],
      "ConditionBrowseLeafName": [
            "Diabetes Mellitus",
            "Kidney Diseases",
            "Diabetes Mellitus, Type 2",
            "Diabetic Nephropathies",
            "Urologic Diseases",
            "Diabetes Complications",
            "Endocrine System Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "low",
            "high",
            "low",
            "high",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000007674",
            "D000003928"
      ],
      "ConditionMeshTerm": [
            "Kidney Diseases",
            "Diabetic Nephropathies"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Triple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator"
      ],
      "DetailedDescription": [
            "The study was a 48-week multicenter, randomized, double-blind, placebo-controlled trial that included 8 weeks of pre-screening and lifestyle education, 32 weeks of treatment, and 16 weeks of follow-up.We plan to recruit 54 subjects\uff0cwhich were divided into experimental group and control group. The volunteers of the experimental group will be given peripheral intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cell (HUC-MSC) at 0,8,16,24,32 week. The control group will be given the same dose of saline. Then centralization visit was conducted every 8 weeks until the 48th week.The primary end points include estimated glomerular filtration rate and urinary albumin creatinine ratio(UACR). The secondary end points include HbA1C,plasma insulin and C-peptide, and insulin dose."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria (in brief):\n\nType 2 diabetes mellitus\nDiabetes duration\u226420 years\n18.5kg/m^2 \u2264 BMI< 30 kg/m^2\n7.5%\u2264HbA1C\u226410%\nUACR\u226530mg/gCr\neGFR \u226545/milliliter/1.73m^2\n\nExclusion Criteria (in brief):\n\nType 1 diabetes mellitus\ntumor history\nOther causes of chronic kidney disease\nAbnormal liver function"
      ],
      "EnrollmentCount": [
            "54"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "experimental group",
            "control group"
      ],
      "InterventionBrowseBranchAbbrev": [
            "PhSol",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Pharmaceutical Solutions",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M21013"
      ],
      "InterventionBrowseLeafName": [
            "Pharmaceutical Solutions"
      ],
      "InterventionBrowseLeafRelevance": [
            "low"
      ],
      "InterventionDescription": [
            "human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group",
            "Saline solution containing human serum albumin will be infused to the control group"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "human umbilical cord mesenchymal stem cells",
            "saline"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Other"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "human umbilical cord mesenchymal stem cells",
            "type 2 diabetic nephropathy"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Recruiting"
      ],
      "LastUpdatePostDate": [
            "December 17, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "December 16, 2020"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Shanghai East Hospital"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Shanghai"
      ],
      "LocationContactEMail": [
            "wcr601@163.com"
      ],
      "LocationContactName": [
            "Congrong Wang, MD"
      ],
      "LocationContactPhone": [
            "+86-021-38804518"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact"
      ],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "Shanghai East Hospital"
      ],
      "LocationState": [
            "Shanghai"
      ],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "200124"
      ],
      "MaximumAge": [
            "70 Years"
      ],
      "MinimumAge": [
            "30 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Shanghai East Hospital"
      ],
      "OrgStudyId": [
            "DFSC-2019(CR)-06"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Shanghai East Hospital, Shanghai Tongji University"
      ],
      "OverallOfficialName": [
            "Zhongming Liu, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "February 1, 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "urinary albumin creatinine ratio"
      ],
      "PrimaryOutcomeMeasure": [
            "UACR"
      ],
      "PrimaryOutcomeTimeFrame": [
            "48weeks after treatment"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "HbA1c",
            "serum level of insulin/C peptide",
            "insulin dosage",
            "estimated glomerular filtration rate"
      ],
      "SecondaryOutcomeMeasure": [
            "HbA1c",
            "insulin/C peptide",
            "insulin dosage",
            "eGFR"
      ],
      "SecondaryOutcomeTimeFrame": [
            "48weeks after treatment",
            "48weeks after treatment",
            "48weeks after treatment",
            "48weeks after treatment"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "July 1, 2020"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "June 2020"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "January 3, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "December 17, 2019"
      ],
      "StudyFirstSubmitQCDate": [
            "December 30, 2019"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}